Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term infliximab (Remicade) in ankylosing spondylitis
2005-002460-29Phase 4Completed
- Sponsor
- Rheumazentrum Ruhrgebiet
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in ankylosing spondylitis (AS), sponsored by Rheumazentrum Ruhrgebiet. Primary endpoint: Radiographic progression after 6 years of infliximab treatment. Started Jul 2005; status: completed.
02
Drugs
infliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2005-002460-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002460-29.